Literature DB >> 2828083

A clinical study of Addison's disease.

G De Rosa1, S M Corsello, L Cecchini, S Della Casa, A Testa.   

Abstract

Fifty-four patients affected by primary adrenocortical insufficiency have been retrospectively studied. Eighteen were affected by a tuberculous Addison's disease, 24 by an idiopathic Addison's disease and 12 by an unclassifiable form. Modality of arise, clinical presentation and association with other diseases are reviewed. The most useful laboratory and instrumental tests for the diagnosis are discussed and a diagnostic flow-chart is proposed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2828083     DOI: 10.1055/s-0029-1210695

Source DB:  PubMed          Journal:  Exp Clin Endocrinol        ISSN: 0232-7384


  5 in total

Review 1.  The endocrinology of adrenal tuberculosis: the effects of tuberculosis on the hypothalamo-pituitary-adrenal axis and adrenocortical function.

Authors:  F Kelestimur
Journal:  J Endocrinol Invest       Date:  2004-04       Impact factor: 4.256

Review 2.  Role of proopiomelanocortin-derived peptides and their receptors in the osteoarticular system: from basic to translational research.

Authors:  Markus Böhm; Susanne Grässel
Journal:  Endocr Rev       Date:  2012-06-26       Impact factor: 19.871

3.  Utility and limitations of biochemical parameters in the evaluation of hyponatremia in the elderly.

Authors:  W Musch; G Decaux
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

4.  Acute adrenocortical failure due to tuberculosis.

Authors:  F Keleştimur; O Ozbakir; A Sağlam; F Oztürk; M Yücesoy
Journal:  J Endocrinol Invest       Date:  1993-04       Impact factor: 4.256

5.  Mixtures of prion substrains in natural scrapie cases revealed by ovinised murine models.

Authors:  Tomás Barrio; Hicham Filali; Alicia Otero; Jessica Sheleby-Elías; Belén Marín; Enric Vidal; Vincent Béringue; Juan María Torres; Martin Groschup; Olivier Andréoletti; Juan José Badiola; Rosa Bolea
Journal:  Sci Rep       Date:  2020-03-19       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.